Welcome to our dedicated page for Zivo Bioscience SEC filings (Ticker: ZIVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ZIVO Bioscience, Inc. (ZIVO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, annual and quarterly reports and other documents filed with the U.S. Securities and Exchange Commission. As a Nevada corporation with a Commission File Number of 000-30415, ZIVO uses these filings to report material events, describe its business and update investors on governance and financial matters.
For a research and development company like ZIVO, SEC filings are a key source of information on its biotech and agtech activities involving proprietary algal and bacterial strains, biologically active molecules and complexes, and related intellectual property. Filings can explain how the company characterizes its focus on human and animal health applications, outline risk factors and summarize relationships with collaborators and counterparties.
Current reports on Form 8-K, such as the filing describing the resignation of a Chief Financial Officer and the appointment of an Interim Chief Financial Officer under an independent contractor services agreement, document significant management changes and associated compensation arrangements. Investors can also use this page to monitor future 10-K annual reports and 10-Q quarterly reports for updates on ZIVO’s R&D programs, liquidity, and any disclosed licensing or collaboration agreements.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in plain language, helping readers quickly understand lengthy documents. Real-time updates from EDGAR ensure that new ZIVO filings appear promptly, while access to ownership and insider transaction reports, such as Form 4 when filed, allows users to track equity-related activity by directors and officers. This combination of raw filings and AI analysis offers a structured way to review ZIVO’s regulatory history and ongoing disclosure record.
ZIVO Bioscience, Inc. plans to voluntarily delist its common stock and warrants from the OTC markets and file a Form 15 to deregister its securities and suspend SEC reporting obligations on or around March 30, 2026. The board concluded that the legal, accounting, and administrative costs of SEC compliance place a significant financial burden on the company and divert resources from its core biotech and agtech R&D operations. Once Form 15 is filed, ZIVO’s obligations to file Forms 10-K, 10-Q, and 8-K will immediately cease. Management states it will continue focusing on animal health and nutrition initiatives, aiming to redirect savings from public-company compliance toward advancing its strategic plan and long-term stockholder value.
Zivo Bioscience director and 10% owner–associated entity buys shares. An entity associated with director and ten percent owner Laith L. Yaldoo, identified as HEP Investment, LLC, made an open-market purchase of 1,543 shares of Zivo Bioscience common stock at $9.72 per share. After this transaction, the filing reports 583,615 shares of common stock indirectly owned.
Strome-affiliated investors updated their ownership in Zivo Bioscience’s common stock. Mark E. Strome now reports beneficial ownership of 472,942 shares, or 12.10% of the company’s 3,888,595 shares outstanding as of November 9, 2025.
Strome Mezzanine Fund II holds 266,198 shares, representing 6.81% of the company, after merging with Strome Mezzanine Fund on December 31, 2025 and becoming the surviving entity. SMF ceased to hold any shares following this merger.
On February 12, 2026, Strome Mezzanine Fund II acquired 20,000 shares of Zivo Bioscience at $9.77 per share under a Securities Purchase Agreement and received a warrant, for no additional consideration, exercisable for 2,000 additional shares at $9.77 per share, subject to adjustments.
Zivo Bioscience reported that investment entities associated with 10% owner Mark E. Strome, through Strome Mezzanine Fund II, LP, bought 20,000 shares of common stock at $9.77 per share and 2,000 common stock purchase warrants on February 12, 2026.
After these indirect purchases, the entities reported beneficial ownership of 472,942 common shares and 45,071 warrants.
Zivo Bioscience insider reporting shows an indirect open-market purchase of common stock tied to director and 10% owner Laith L. Yaldoo. On 02/10/2026, HEP Investments LLC, an entity associated with Yaldoo, bought 2,434 shares of Zivo Bioscience common stock at $10.27 per share. Following this transaction, HEP Investments LLC indirectly held 582,072 shares of common stock.
Zivo Bioscience director Alison Cornell reported buying additional company stock. On January 26, 2026, she purchased 11,709 shares of common stock at a price of $8.54 per share. Following this transaction, she directly beneficially owns 279,481 shares of Zivo Bioscience common stock.
Zivo Bioscience, Inc. President and CEO John B. Payne reported an open-market purchase of company stock. On 01/26/2026, he bought 11,709 shares of common stock at $8.54 per share. Following this transaction, he directly owns 19,618 shares of Zivo Bioscience common stock.
Zivo Bioscience director and 10% owner Christopher D. Maggiore reported a small open-market purchase of common stock. On 01/14/2026, he bought 1,766 shares of Zivo Bioscience common stock at a price of $8.49 per share, coded as a purchase transaction.
Following this trade, Maggiore beneficially owned 519,292 shares of Zivo Bioscience common stock in direct ownership form, indicating his stake as both a director and a more than 10% shareholder.